Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 1/20 | 0.57 |
| ▸ | TBK1 | Q9UHD2 | 4/20 | 0.55 |
| ▸ | PAK1 | Q13153 | 4/20 | 0.54 |
| ▸ | BTK | Q06187 | 3/20 | 0.53 |
| ▸ | CSF1R | P07333 | 2/20 | 0.52 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.50 |
| ▸ | BMPR1B | O00238 | 2/20 | 0.47 |
| ▸ | BMPR1A | P36894 | 2/20 | 0.47 |
| ▸ | ACVRL1 | P37023 | 2/20 | 0.47 |
| ▸ | ACVR1 | Q04771 | 2/20 | 0.47 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.46 |
| ▸ | WDR5 | P61964 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.46 |
| ▸ | EGFR | P00533 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4065929 | 0.89 | RIPK1 (0.60) | RIPK1TBK1BTKALKWDR5 | |
| SCHEMBL4068131 | 0.86 | RIPK1 (0.57) | RIPK1TBK1BTKALKEGFR | |
| SCHEMBL4068055 | 0.84 | RIPK1 (0.55) | RIPK1TBK1BTKCSF1RALK | |
| SCHEMBL13604150 | 0.83 | RIPK1 (0.61) | RIPK1TBK1BTKALKWDR5 | |
| SCHEMBL4467935 | 0.83 | RIPK1 (0.64) | RIPK1TBK1BTKALKPRMT5 | |
| SCHEMBL4463465 | 0.83 | RIPK1 (0.53) | RIPK1TBK1BTKCSF1RALK | |
| SCHEMBL4472467 | 0.82 | RIPK1 (0.52) | RIPK1TBK1BTKALKWDR5 | |
| SCHEMBL4063817 | 0.82 | RIPK1 (0.59) | RIPK1TBK1BTKCSF1RALK | |
| SCHEMBL4769173 | 0.81 | RIPK1 (0.53) | RIPK1TBK1BTKWDR5KMT2A | |
| SCHEMBL4068059 | 0.78 | RIPK1 (0.55) | RIPK1TBK1BTKCSF1RALK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070135460-A1 | 7H-pyrrolopyrimidine derivatives | CARAVATTI GIORGIO | 2007-06-14 | — | — | US | claimed |
| CN-1922184-A | 7H-pyrrolopyrimidine derivatives | NOVARTIS AG (CH) | 2007-02-28 | — | — | CN | claimed |
| EP-1718651-A2 | 7H-PYRROLOPYRIMIDINE DERIVATIVES | Novartis AG (CH) | 2006-11-08 | — | — | EP | claimed |
| WO-2005077951-A2 | 7H-PYRROLOPYRIMIDINE DERIVATIVES | NOVARTIS AG (CH) | 2005-08-25 | — | — | WO | claimed |
| US-7625894-B2 | Pyrrolo[2,3-d]Pyrimidines as Protein Tyrosine Kinase Inhibitors | NOVARTIS AG (CH) | 2009-12-01 | — | — | US | disclosed |
| US-20070135460-A1 | 7H-pyrrolopyrimidine derivatives | CARAVATTI GIORGIO | 2007-06-14 | — | — | US | disclosed |
| CN-1922184-A | 7H-pyrrolopyrimidine derivatives | NOVARTIS AG (CH) | 2007-02-28 | — | — | CN | disclosed |
| EP-1718651-A2 | 7H-PYRROLOPYRIMIDINE DERIVATIVES | Novartis AG (CH) | 2006-11-08 | — | — | EP | disclosed |
| WO-2005077951-A2 | 7H-PYRROLOPYRIMIDINE DERIVATIVES | NOVARTIS AG (CH) | 2005-08-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135460-A1 | 7H-pyrrolopyrimidine derivatives | DPYD, TYMP, DHPS | RIPK1 3871/4885TBK1 2979/4885PAK1 1139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.